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Background: Allogeneic hematopoietic stem cell transplantation (alloHSCT) has been
proposed as curative approach for advanced cutaneous T–cell lymphomas (CTCL).
Currently, there is no established consensus for the management of disease relapse
after alloHSCT.
Results: Ten patients, previously treated with multiple lines of systemic treatment,
received alloHSCT. Six patients had achieved partial response (PR, N = 5) and complete
response (CR, N = 1) prior to HSCT. Post—HSCT, seven patients (N = 7) relapsed
after a median time of 3.3 months (0.5–7.4 months) and were subsequently treated with
radiotherapy (RT,N= 1), RT and adoptive T-cell transfer with EBV specific cells (N= 1), R-
CHOP (N = 1) and interferon alpha−2a combined either with donor lymphocyte infusion
(N = 1) or with brentuximab—vedotin (N = 1). One patient (N = 1) achieved PR only after
reducing the immunosuppression. Two patients relapsed again and received interferon
alpha−2a and brentuximab—vedotin, respectively. After a median follow-up time of 12.6
months (3.5–73.7 months) six patients were alive (60%) and four had deceased, three
(N = 3) due to CTCL and one (N = 1) due to GVHD.
Conclusion: Disease relapse after alloHSCT can be controlled with available treatments.
For most patients who ultimately relapsed, reduction of immunosuppression and
interferon alpha−2a either administered alone or in combination with another systemic
agent were preferred. Although interferon alpha−2a, similarly to immunosuppression
reduction, may be beneficial for the achievement of graft–vs.–lymphoma effect, the
risk of simultaneous worsening of GVHD must be carefully evaluated and taken
into consideration.
Keywords: allogeneic stem cell transplantation, cutaneous T-cell lymphoma, Sézary syndrome, mycosis
fungoides, interferon alpha-2a
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INTRODUCTION
Primary cutaneous T–cell lymphomas (CTCL) are a
heterogeneous group of non–Hodgkin lymphomas (NHL)
of skin—homing T–cells (1, 2). CTCL account for ∼2% of all
lymphomas and mycosis fungoides (MF) comprise the majority
of cases. Most patients with MF present a prolonged, indolent
clinical course with initial skin involvement and subsequent
progression in certain cases to the lymph nodes and visceral
organs (3, 4). Early disease stages can be controlled with skin—
directed therapy, such as topical steroids, light treatment and
radiation (5). Sézary syndrome (SS) is a rare (2–5%), aggressive
leukemic variant of CTCL with systemic features in addition
to skin involvement, characterized by low complete response
(CR) rates to therapy (3, 4). Advanced MF and SS have a
dismal prognosis and warrant systemic therapy; yet, long—term
remission rates with conventional treatments alone are still
low (5).
Hematopoietic stem cell transplantation (HSCT) has been
explored as a curative option in patients with advanced—
stage CTCL and has shown promising disease control (DCR)
and overall survival (OS) rates (6, 7). A patient—level meta—
analysis has implied that autologous HSCT results only in limited
responses with OS and progression—free survival (PFS) inferior
to allogeneic HSCT; therefore, autologous HSCT in CTCL is
currently barely used (8). Several sets of clinical data have
indicated that allogeneic HSCT could provide a cure in patients
with previously incurable disease (7). Although randomized
clinical trials comparing HSCT and conventional systemic
therapies are missing, OS rates after HSCT are encouraging and
are estimated at 46 and 44% at 5 and 7 years, respectively (9–11).
Nevertheless, about 50% of the patients will relapse during the
first year post—HSCT, with a median time of disease relapse at
3.8 months (9). Although most cases describe local, manageable
skin relapse, hematological relapse has been associated with a
poor prognosis (9). To date, there is yet no established consensus
for the management of disease relapse after HSCT. Herein, we
report the results of a single center, retrospective analysis of ten
CTCL patients treated with alloHSCTwith a long—term follow—
up and we aim to discuss possible therapeutic strategies for the
management of disease relapse after alloHSCT.
METHODS
Medical records of 215 patients diagnosed with CTCL in
the Dermatology clinic of the University Hospital of Zurich
between 2012 and 2019 with a closing date of February 2020
were reviewed. Clinical data of patients who underwent HSCT
were retrospectively collected. Two patients (N = 2) who
underwent an autologous HSCT were excluded. In total, ten
(N = 10) patients with advanced—stage CTCL (stages IIB
and higher) who underwent a first alloHSCT were identified
and further analyzed. Minimum follow—up after HSCT was
set to 3 months. Baseline demographic characteristics, disease
and transplantation characteristics were collected through their
medical records. Diagnosis was based on local clinic and
histologic review. TNM classification was adopted according to
TABLE 1 | Baseline characteristics and alloHSCT characteristics (N = 10).






















Total lines of therapy before alloHSCT, excluding
conditioning regimen (median, range)
4 (1–5)











Busulfan, fludarabine and anti–thymocyte
globulin (ATG)
9





Cyclosporine and MMF 9
Ciclosporine, MMF, Cyclophosphamide 1
Disease relapse post–alloHSCT, n 7
Time of alloHSCT to first relapse, months
(median, range)
3.3 (0.5–7.4)
Time to next treatment, months (median, range) 8.1 (1.9–9.4)
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PUVA, psoralen and ultraviolet A; MTX, methotrexate; CR, complete response; PR,
partial response; PD, progressive disease; alloHSCT, allogeneic hematopoietic stem cell
transplantation; GVHD, graft vs. host disease; MMF, mycophenolate mofetil.
the International Society for Cutaneous Lymphomas (ISCL) and
the European Organization of Research and Treatment of Cancer
(EORTC) (1, 12). Data analysis focused on disease outcome,
including progression—free survival (PFS, defined as date of
HSCT to disease progression), time to next treatment (TTNT,
defined as stop date of HSCT to date of next treatment initiation)
and overall survival (OS, defined as time from HSCT start until
last visit or death). End points were assessed on the date of last
patient contact. Follow—up time was calculated from the start
date of alloHSCT to the date of last follow-up, including last
visit or date of death, or February 2020, whichever occurred first.
Patients alive at the end of follow—upwere censored. All analyses
were conducted using statistical language R version 3.5. Reported
p-values were accepted as statistically significant if <0.05.
Written informed consent for retrospective analysis of CTCL




Clinical characteristics are summarized in Table 1. A total
of ten patients with CTCL and median age of 56.5 years
(range 22–66) were included. Seven patients were males (7/10)
and three were females (3/10). CTCL type included mycosis
fungoides and folliculotropic mycosis fungoides (MF and FMF,
N = 7), Sézary syndrome (SS, N = 1), extranodal EBV+
NK/T–cell lymphoma, nasal type (NNKTL, N = 1) and
aggressive epidermotropic cytotoxic T-cell lymphoma (AECTCL)
as composite lymphoma with chronic lymphocytic leukemia
(CLL) (N = 1). Three patients (N = 3) diagnosed with
FMF had an advanced disease with histologically follicle—
based infiltrated tumors, which is associated with an aggressive
course and dismal prognosis (13). Large cell transformation
(LCT) was present in one of these patients (1/3, patient Nr.
8). Staging information during the initial CTCL diagnosis is
summarized on Supplementary Table 1, available at Frontiers in
Medicine supplement.
In total, eight patients had received three or more lines
of systemic therapy prior to HSCT. Excluding HSCT and
conditioning regimen, themedian number of treatment regimens
received was 4 (range 1- 5). Treatments included PUVA (N
= 7), methotrexate (MTX, N = 4), retinoids (N = 5), IFN—
alpha (N = 8) and mogamulizumab (anti-CCR4 monoclonal
antibody, N = 1) in terms of a clinical trial (NCT01728805).
Three patients with CD30+ MF received brentuximab—
vedotin (anti-CD30 monoclonal antibody, N = 3) in terms
of a clinical trial (NCT01578499). Eight patients (N = 8)
received chemotherapy as tumor debulking therapy prior to
HSCT, including CHOP, R–CHOP plus etoposide, doxorubicin,
pralatrexat, vorinostat, gemcitabine, asparaginase, ifosfamide and
DHAP (dexamethasone, high-dose AraC, platinol). Complete
remission (CR) of disease was achieved in only one patient
prior to alloHSCT (N = 1). Five patients (N = 5) were in
partial remission (PR), whereas four patients (N = 4) experienced
disease progression (PD).
Allogeneic Hematopoietic Stem Cell
Transplantation (alloHSCT)
AlloHSCT characteristics are summarized in Table 1. In all, ten
patients (N = 10) underwent allogeneic hematopoietic stem
cell transplantion. The vast majority of the patients received
a reduced—intensity conditioning (RIC) regimen including
busulfan, fludarabine and anti—thymocyte globulin (ATG) (N =
9) whereas one patient (N = 1) received busulfan, fludarabine
and thiotepa. Donor type for alloHSCT was matched unrelated
in seven patients and matched related in three patients. CR
was achieved in eight patients after alloHSCT. One patient with
NNKTL (N = 1) and one with FMF (N = 1) did not respond to
the alloHSCT (PD). The overall response rate (ORR) at month
3 after HSCT was 80% (CR, N = 7 and PR, N = 1); during
this time, disease relapse occurred in one patient with FMF at
58 days post–HSCT. As of February 2020, three patients (30%)
remained free – of disease relapse and six patients (60%) were
alive since alloHSCT.
Graft vs. Host Disease (GVHD)
GVHD prophylaxis consisted of cyclosporine and
mycophenolate mofetil (MMF) in nine alloHSCT patients
(N = 9). One patient (N = 1) received GVHD prophylaxis
with cyclosporine, MMF and cyclophosphamide. Acute GVHD
developed in eight of ten patients (grade 1, N = 1; grade 2, N
= 4; grade 3, N =1; grade 4, N = 2). One patient with NNKTL
deceased due to grade IV GVHD with cutaneous, pulmonary
and gastrointestinal manifestation, 14.6 months after alloHSCT.
Disease Progression, Relapse and
Outcome
Seven patients (N = 7) relapsed after a median time of 3.3
months (0.5–7.4 months). Four out of seven (4/7) patients
who experienced disease—relapse received further systemic
treatment, three of which (3/7) in combination with skin—
directed treatment for cutaneous relapse (radiotherapy (RT),
operation). Systemic treatments included adoptive T–cell transfer
with EBV specific cells (N = 1) interferon alpha-2a combined
either with donor lymphocyte infusion (N = 1) or with
brentuximab—vedotin (N = 1) and R-CHOP in one (N =
1) patient with AECTCL due to rapid disease progression
post—alloHSCT. One patient (1/7) with SS received only RT
for cutaneous disease and in one (1/7) patient, reduction of
immunosuppression without any subsequent treatment resulted
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FIGURE 1 | Treatment course of the ten patients who underwent allogeneic hematopoietic stem cell transplantation (alloHSCT).
in disease control. Systemic treatment was not considered in one
patient (1/7) due to reduced performance status.
Two patients (Nr. 1 and 2, presented on
Supplementary Table 1), each experienced two disease relapses.
The first patient (Nr. 1) initially relapsed 7.4 months after
alloHSCT and received a skin—directed treatment with
radiotherapy. During the second relapse 9.6 months post—
alloHSCT, a systemic treatment with interferon alpha−2a
was initiated with subsequent CR. The second patient (Nr. 2)
initially relapsed 6 months after alloHSCT and was treated with
interferon alpha−2a in combination with donor lymphocytes.
The second relapse occurred after 15.1 months post-alloHSCT
and treated with brentuximab—vedotin with subsequent PR.
Median TTNT was 8.1 months (1.9–9.4 months). ORR was
57.1% (CR, N=2; PR, N = 2).
After a median follow-up time of 12.6 months (3.5–73.7
months) post—alloHSCT, six patients were alive (60%) and four
had deceased, three (N = 3) due to CTCL progression and one
(N = 1) due to GVHD. Treatment course and follow—up data
for the all patients who underwent HSCT are summarized in
Figure 1 and Supplementary Table 1 available at Frontiers in
Medicine supplement.
Overall Survival (OS) and
Progression—Free Survival (PFS)
The results for OS and PFS for all CTCL types are provided
in Figure 2. PFS was 25% at 12 months and OS 62.5 and
50% at 12 and 24 months, respectively. A separate analysis was
performed to evaluate the disease control and outcome after
alloHSCT for patients diagnosed with MF, FMF, and SS, due
to the different nature of the two other lymphomas (NNKTL
and AECTCL) and their possible impact on PFS and OS. PFS
for this patient group was 30% at 12 months and OS 65% at
6, 12 and 24 months (Figure 2). We further analyzed the OS
and PFS rates according to the disease status prior to transplant
(Figures 3A,B) and timing of transplant (Figures 3C,D), with a
cut—off 36 months from disease diagnosis. We found no benefit
on PFS andOS on “earlier” transplants (<36months after disease
diagnosis) compared to “later” transplants (p= 0.94 and p= 0.58,
respectively). Concerning the disease status prior to transplant,
we compared recipients withminimal residual disease (CR or PR)
before HSCT with patients having PD. There was a statistically
non-significant difference on PFS (p = 0.28) in favor of CR/PR
compared to PD prior to HSCT. Though, no difference on OS
was found (p = 0.86), which can be explained by the systemic
treatment initiation after disease relapse. Indeed, only one patient
(N = 1) with stage IVB MF and PD prior to HSCT deceased due
to lymphoma.
DISCUSSION
According to the literature, about 70% of the CTCL cases,
including mostly MF and SS, present with early disease stage
(IA–IIA) and are associated with a favorable prognosis and 5–
year OS survival rates of 96–99% (14–16). Patients with advanced
disease stages have a poor prognosis and often warrant a systemic
treatment (5). In a recent study, median OS for advanced, stage
IIB, IVA and IVB MF and SS was 68, 48, and 33 months,
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FIGURE 2 | Probability of (A) overall survival (OS) and (B) progression—free survival (PFS) after allogeneic hematopoietic stem cell transplantation (alloHSCT) for the
study population. OS (C) and PFS (D) after alloHSCT for patients with Sézary syndrome (SS), mycosis fungoides (MF) and folliculotropic mycosis fungoides (FMF).
respectively (17). Although diverse systemic treatment options
are available, ORR with newer agents average 30–40% with scarce
data concerning long—term disease control (17, 18). Current
guidelines recommend alloHSCT as a second—line treatment
option from stage IIB ofMF (evidence level 3) and in SS (evidence
level 3) for eligible patients to improve survival (18).
In this retrospective study, we describe the outcomes of
ten patients with extensively pretreated, advanced CTCL who
underwent alloHSCT in a single—center cohort. Since autoHSCT
is no longer sought as a treatment modality in CTCL patients
(8), these patients were excluded from the current analysis.
The vast majority of the CTCL types included MF and SS.
Three cases diagnosed with FMF had an advanced disease type,
which is associated with an aggressive disease course and thus,
dismal prognosis (13). Besides, rare entities with historically poor
prognosis, such as NNKTL and AECTCL were also identified and
included in the analysis (19). Due to the different nature of these
two CTCL types compared to MF and SS, a separate analysis
evaluating the PFS and OS rates only on MF/FMF and patients
was performed. In the present study, the OS rate for the patient
population was 62.5 and 50% at 1 and 2 years, respectively, and
the PFS 25% at 1 and 2 years. Most patients seem to progress
early after the HSCT; PFS at 5 months was 60% and 3 months
after HSCT ORR was 80%, with seven patients reaching CR.
For patients diagnosed with either MF/FMF or SS, PFS was
30% at 12 months and OS 65% at 6 months, with sustainable
responses at 12, 18, and 24 months post—HSCT. Although a
direct comparison with previously reported studies is difficult
and could be misleading, these sustainable responses seem to
be similar to those described for alloHSCT (20, 21). Extended
analysis from retrospective published data reported OS of 46 and
44% at 5 and 7 years for alloHSCT in patients with MF or SS (22).
In our patient cohort, as of February 2020 and with
a median follow—up time 12.6 months (3.5–73.7 months),
60% of the patients were alive. Transplant—related mortality
was low; out of the four patients that deceased, one patient
developed stage IV GVHD (time from HSCT 14.6 months).
Grade IV GVHD was observed in one patient with MF, though
still alive at the data closing date. GVHD rates of varying
severity grades were observed in eight out of ten patients
who underwent an alloHSCT with three patients developing
grade III and IV GVHD. De Masson at al suggested an
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FIGURE 3 | Probability of (A) overall survival (OS) and (B) progression—free survival (PFS) according to disease status prior to allogeneic hematopoietic stem cell
transplantation (alloHSCT) (comparing recipients with minimal residual disease (CR or PR) with patients on PD before HSCT). OS (C) and PFS (D) according to time till
alloHSCT with a cut–off 36 months from disease diagnosis.
antigenic stimulation by residual tumor cells as a possible
mechanism of these high GVHD incidence rates in CTCL
patients following alloHSCT (21). In this study, we did not
observe any direct association of GVHD development with
remission status before transplantation. Nevertheless, GVHD has
been previously associated with prolonged PFS, presumably due
to simultaneous graft—vs.—lymphoma (GVL) effect (23, 24).
A considerable number of patients in this study (N =
7) experienced disease relapse after a median time of 3.3
months (0.5–7.4 months), confirming previous data suggesting
that the majority of relapses occur within the first year
post—transplant. Most patients who experienced relapse post—
HSCT were induced back into remission by skin—directed or
systemic treatment, as well as reduction of immunosuppression.
Systemic treatment was not considered in one patient due to a
reduced performance status. In the vast majority of the patients
who relapsed (N = 3), reduction of immunosuppression and
systemic treatment with IFN—alpha in combination with donor
lymphocytes and brentuximab vedotin was preferred, attempting
to increase the antitumor effect. Indeed, some cases have
currently provided clinical evidence of a GVL effect in patients
with MF/SS (23, 25, 26), supporting that immunosuppression
reduction and IFN—alpha may promote an immune-mediated
GVL effect in patients who underwent an alloHSCT. Preclinical
data on mouse models confirm that type 1 interferons enhance
protective GVL responses through donor cell production of
IFNα/β, thus providing experimental support for IFN—alpha as a
treatment option in individuals at high risk of relapse after HSCT
(27). Nevertheless, the risk of simultaneous induction and/or
worsening of post-transplant GvHD with severe consequences
must be carefully evaluated and taken into clinical consideration.
The timing of HSCT and choice of conditioning regimen are
subject to controversy. In our patient cohort, RIC with busulfan,
fludarabine and anti—thymocyte globulin (ATG) was previously
used in the majority of the patients who underwent an alloHSCT
to allow treatment in patients with comorbidities, multiple
previous treatment—lines and advanced disease stage. Although
the ideal conditioning regimen for HSCT in CTCL patients is
unknown, recent studies suggest that RIC reduces the mortality
rates seen with myeloablative conditioning regimen (MAC)
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with equivocal efficacy and should be therefore recommended
in eligible patients undergoing alloHSCT (11, 20, 28). A less
intensive approach with non-myeloablative preparative regimen
using total lymphoid irradiation (TLI) and anti-thymocyte
globulin (ATG), without chemotherapy, is currently investigated
in a phase−2 clinical trial (NCT00896493) with promising
preliminary results (29).
In this study, we could not find any significant difference
between “earlier” (< 36 months after disease diagnosis)
compared to “later” transplants on OS and PFS. However, this
may be explained by the small patient cohort. Retrospective
studies on larger patient cohorts have linked worse OS,
reduced PFS and increased risk of disease relapse to advanced
stage of disease at the time of HSCT (11, 22). Although
the optimal timing for HSCT has not been yet determined,
we recommend early consultation of a transplant physician
in transplant eligible patients, in line with the EORTC
recommendations (18).
A main strength of our study is the detailed clinical data and
follow—up information available for CTCL patients, including
those treated with HSCT at our institution. However, the small
number of patients, the retrospective nature of the data and the
heterogeneity of CTCL are possible limitations of this analysis.
Given the rarity of CTCL and the high—quality follow—up data
on HSCT in CTCL, our study provides interesting conclusions
on the effect of HSCT in CTCL and the management of relapses
from a single center. We conclude that alloHSCT may induce
durable responses and should be therefore considered as a
treatment option for patients with advanced or treatment—
refractory CTCL, especially for patients with more aggressive
CTCL subtypes, such as advanced stage folliculotropic MF
or presence of large cell transformation. In accordance with
previous studies (29) and with the current guidelines (18), we
recommend alloHSCT for patients with MF/SS with advanced
disease stages (IIB to IV) who are in first or second CR, PR or
relapse/progression having received three or fewer prior lines of
systemic therapy. Regarding the conditioning regimen, Duarte
et al. showed that using RIC regimens decreased the non-relapse
mortality (NRM) significantly without increasing the risk of
relapse (9). This led to a better OS, also in younger patients.
The RIC we routinely use includes fludarabin, busulfan and
ATG (for unrelated and related donors). Furthermore, there
are many case reports which provide evidence of a graft—vs.–
tumor effect in patients with MF/SS. Duarte al reported that
50% patients with a relapse after alloHSCT achieve a CR after
receiving donor lymphocyte Infusion (DLI) (9). However, there
is too little data to recommend prophylactic DLI in this patient
group.We recommend that disease relapse post-alloHSCTshould
be promptly treated with reduction of immunosuppression
and immunomodulatory agents, in order to control relapse
and to enhance graft—vs.—lymphoma effect. However, further
improvements to control the severity of GVHD need to
be pursued.
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